MedTrace Logo

Oral Metformin for Treating Melasma in Latin American Women

NCT06845540 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-25

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if metformin can treat melasma in Latin American women. The main question it aims to answer is:

\- Can metformin help reduce the dark patches of melasma?

Researchers will test two different doses of metformin (500 mg and 1000 mg) to see if either one helps improve melasma.

Participants will:

* Take a metformin pill every day for three months.
* Go to the clinic twice: once at the beginning and once at the end of the study.
* Get a phone call from the researchers to check how they're doing and ask about any changes or side effects.

Conditions

  • Melasma

Interventions

DRUG

Metformin

Participants received oral metformin tablets for the treatment of melasma. The initial dose was 500 mg once daily for four weeks. At week 4, participants who tolerated the medication well increased their dose to 500 mg twice daily for the remaining eight weeks of the study. Participants were instructed to avoid other melasma treatments during the trial and to use sunscreen (SPF 30 or higher) daily.

Sponsors & Collaborators

  • University of Puerto Rico

    lead OTHER

Principal Investigators

  • Cristina Brau · University of Puerto Rico

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2025-05-22
Completion
2025-05-30
FDA Drug
Yes

Countries

  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845540 on ClinicalTrials.gov